Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Ironwood Pharma (IRWD) Stock Price & Analysis
228 Followers
IRWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.47 - $15.70
Previous Close$6.11
Volume1.29M
Average Volume (3M)2.68M
Market Cap
$971.23M
Enterprise Value$1.54B
Total Cash (Recent Filing)$121.54M
Total Debt (Recent Filing)$690.42M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 01, 2024EPS Estimate
$0.16Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding158,957,123
10 Day Avg. Volume3,511,523
30 Day Avg. Volume2,677,636
Standard Deviation0.11
R-Squared0.06
Alpha-0.00941
Financial Highlights & Ratios
Price to Book (P/B)-2.90
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)5.40
P/FCF Ratio6.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$16.75Price Target Upside158.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Ironwood Pharma News
PremiumCompany Announcements
Ironwood Pharma Elevates CFO and Repays Convertible Notes
PremiumPre-Earnings
Is IRWD a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessApraglutide met the primary endpoint and two of the four secondary endpoints in the clinical trial.
Competitive AdvantageThe real differentiation for Apra remains the convenient QW administration, which might be a significant advantage over Gattex (QD).
Market PotentialAnalysts reiterate peak revenue potential of ~$500M in SBS-IF due to IRWD's strong commercial execution.
Bears Say
Drug EfficacyInvestor concerns arose when two secondary endpoints for a specific patient group were not met, casting doubt on the drug's overall benefit.
Financial PerformanceShares dropped significantly and hit a 5-year low after an unexpected revenue miss linked to a substantial gross-to-net adjustment.
Revenue GuidanceThe company lowered its financial guidance for the upcoming year, anticipating a decline in key product sales instead of the previously expected growth.
---
Ownership Overview
24.50% Insiders
31.99% Mutual Funds
33.74% Other Institutional Investors
9.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $5.47 and its highest was $15.70 in the past 12 months.
What is Ironwood Pharma’s market cap?
Currently, no data Available
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Aug 01, 2024 which is in 26 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on May 09, 2024. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of $0.202 by -$0.232.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.29 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is $0.16.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 158,957,120 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of -$0.03 in its last earnings report, missing expectations of $0.202. Following the earnings report the stock price went down -16.995%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is First Eagle Investment Management LLC. It holds Ironwood Pharma’s shares valued at 9M.
---
Ironwood Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.75 (158.09% Upside)
$16.75 (158.09% Upside)
Blogger Sentiment
Neutral
IRWD Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.19%
12-Months-Change
Fundamentals
Return on Equity
-559.14%
Trailing 12-Months
Asset Growth
-62.02%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q1 2024
0:00 / 0:00
---
IRWD Stock 12 Month Forecast
Average Price Target
$16.75
▲(158.09% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+8.61%
assigned a buy rating 2 months ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +8.61% per trade.
---